Bagsværd, Denmark – March 27, 2026
Novo Nordisk announced that the U.S. FDA has approved Awiqli® (insulin icodec-abae), the first and only once-weekly basal insulin for adults with type 2 diabetes, marking a major breakthrough in diabetes treatment innovation and patient convenience. The approval introduces a new paradigm in insulin therapy, reducing the burden of daily injections to a single weekly dose, while maintaining effective glycaemic control and safety comparable to daily basal insulin therapies.
Breakthrough Weekly Insulin Redefines Diabetes Care
The approval of Awiqli® represents a significant advancement in chronic disease management, as it is the first FDA-approved once-weekly basal insulin, offering a transformative alternative to traditional daily insulin regimens. Designed to improve treatment adherence and patient quality of life, Awiqli® allows patients to shift from seven injections per week to just one, addressing a major challenge in long-term diabetes care.
This innovation is particularly important for patients struggling with treatment fatigue, adherence issues, and complex dosing schedules, which often lead to suboptimal glycaemic control. By simplifying therapy, Awiqli® aims to enhance patient compliance, convenience, and clinical outcomes, making it a high-impact advancement in endocrinology and metabolic disease treatment.
Strong Phase 3 Clinical Program Validates Efficacy
Advertisement
The FDA approval is based on results from the ONWARDS Phase 3a clinical program, which included four randomized, active-controlled trials involving approximately 2,680 adults with type 2 diabetes. Across these studies, Awiqli® demonstrated statistically significant reductions in HbA1c levels, confirming its ability to effectively control blood glucose levels in diverse patient populations.
The trials evaluated Awiqli® in combination with mealtime insulin, oral anti-diabetic drugs, and GLP-1 receptor agonists, reflecting real-world treatment scenarios. Importantly, the therapy showed a safety profile consistent with existing daily basal insulin treatments, reinforcing its suitability for long-term use. These findings highlight the drug’s potential to become a standard-of-care option in type 2 diabetes management.
Expanding Global Access and Commercial Strategy
Novo Nordisk plans to launch Awiqli® in the United States in the second half of 2026, with administration through the FlexTouch® device, further enhancing ease of use. The drug is already approved in multiple global markets including the EU and additional countries, reflecting a strong global regulatory and commercialization strategy.
The approval underscores Novo Nordisk’s commitment to advancing insulin innovation and expanding patient access, especially at a time when parts of the industry are reducing focus on insulin therapies. By continuing to invest in next-generation diabetes treatments, the company aims to support millions of patients worldwide who rely on insulin for daily disease management.
Overall, the FDA approval of Awiqli® highlights the growing importance of patient-centric drug development, long-acting formulations, and simplified treatment regimens in modern healthcare. As diabetes prevalence continues to rise globally, innovations like once-weekly insulin are expected to play a crucial role in improving clinical outcomes, adherence, and healthcare system efficiency, positioning Awiqli® as a landmark advancement in diabetes therapeutics.
Source: Novo Nordisk press release
